METTL3 and lip and oral cavity carcinoma: The METTL3/SALL4 axis, which activates the Wnt/β-catenin pathway post-radiation therapy, enhances the CSC phenotype and leads to radio-resistance in oral cancer, representing a potential therapeutic target to eliminate radio-resistant oral cancer cells [66].